Conformetrix News

 

Future Events

Meet Conformetrix! Our commercial director Dr Gordon Barker will be attending the BIO International Convention in Chicago (2 - 6 May 2010).

 

March 2010

Conformetrix CEO Dr Andrew Almond gave an invited talk to the annual American Chemical Society meeting in San Francisco. Andrew's presentation was part of the prestigious 'Paradigm Shift' series of talks at the event.

 

February 2010

Conformetrix validates its ligand-based discovery platform by identifying novel chemical scaffolds for two disease targets in just 8-weeks. There are currently no approved therapeutic interventions for either the GPCR or ion-channel targets selected for the study.

 

November 2009

Conformetrix secures the first investment from Aquarius Equity Partners' new Origin Fund.

 

October 2009

Conformetrix attends the BioPartnering Europe conference in London.

 

September 2009

Conformetrix appoints Dr Sam Williams (CEO of Modern Biosciences) as non-exec director.

 

July 2009

Conformetrix publishes work on the alpha-7 nicotinic receptor in collaboration with scientists at Oxford, Kinki and Kyoto Universities.

 

April 2009

Conformetrix is awarded a prestigous GRAND award for innovative R&D by the NWDA.

 

March 2009

Conformetrix launches its new virtual screening service. You can learn more about this cutting-edge technology at the EuroCUP computational chemistry workshop in Toledo, Spain (22-24 April).

 

February 2009

Conformetrix attends Biopartnering North America (2009) in Vancouver.

 

December 2008

Conformetrix wins the Bionow Start-up of the Year (2008) Award.

 

June 2008

Conformetrix relocates to offices within the University of Manchester Core Technology Facility.

 

March 2008

Conformetrix awarded a competitive career development training grant from the University of Manchester.

 

January 2008

Conformetrix Ltd proves platform technology is scalable on HPC architecture.

 

November 2007

Conformetrix Ltd locates to commercial offices within the University of Manchester Bioscience Incubator Building.

 

September 2007

Conformetrix awarded a second follow-on funding grant from the BBSRC.

 

July 2007

Conformetrix CEO (Dr. Andrew Almond) awarded a comptetive Royal Society of Edinburgh / BBSRC Enterprise Fellowship. This enables him to take advantage of entrepreneurial training courses and to access a network of mentors.

 

June 2007

Conformetrix awarded BBSRC follow-on funding to further develop platfom technology and speed up turn-around times for service offerings.

 

May 2007

Conformetrix awarded proof of principle funds from University of Manchester Intellectual Property Ltd (UMIP). to test their platform technology on a range of drug targets.